A large cross-sectional study of over 65,000 dermatology patients found that individuals living in lower socioeconomic neighborhoods had significantly higher odds of receiving a new diagnosis of hidradenitis suppurativa, with risk decreasing across increasing SES levels.
The FDA has approved roflumilast (ZORYVE) foam 0.3% for once-daily treatment of plaque psoriasis in patients aged 12 and older, including hard-to-treat scalp and body areas..
Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.